Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers

PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers

US Patent 10948492 · Granted Mar 16, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of assessing the efficacy of a test agent for modulating programmed death2025
Therapeutic treatment of microsatellite unstable cancers2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor 2025
Methods for upregulating immune responses using combinations of anti-RGMb and an2024
KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof2024
Compositions and methods for treating cancer using RHOA dominant negative forms2024
Antibody molecules to PD-1 and uses thereof2023
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatm2023
Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutraliz2023
Compositions and methods for identification, assessment, prevention, and treatme2023
Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, metho2022
Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof2022